Illuminas provides research solutions in various industries including technology, financial services, and healthcare. Self-described capabilities include quantitative and qualitative research, advanced analytics, and data visualization.

Illuminas

AI in Pharma: Discovery is focused on exploring the applications of AI-based technology in drug discovery and development, specifically how AI, ML, NLP, data science, and generative deep learning models can optimize the pharmaceutical and biotechnology industries.

AI in Pharma: Discovery

Codon Genomics is involved in sequencing and bioinformatics, specifically in agrigenomics, pathogen research, and fundamental sciences. They also provide data collection and software solutions along with consultation and training services.

Codon Genomics

Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+.The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical trials; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers, which is in Phase 1 clinical trials. It has collaboration and license agreements with Merck Collaboration to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; and Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.

Metric
Company Name	Illuminas	AI in Pharma: Discovery	Codon Genomics	Sutro Biopharma, Inc.
Symbol				STRO
MSH ID	COM:ILLUMINAS	COM:AIINPHARMA-DISCOVERY	COM:CODONGENOMICS	COM:SUTROBIO
Market	PRIVATE	PRIVATE	PRIVATE	STOCKS
Sector	Commercial & Professional Services	Healthcare & Health Services	Healthcare & Health Services	Healthcare
Industry	Market Research	Pharmaceuticals	Biotechnology	Biotechnology
Country	UK	US	US	US
Stage				Post-IPO Equity
Employee Count				300
Website	illuminas.com	aiinpharma-discovery.com	codongenomics.com	sutrobio.com
LinkedIn
Founders

Metric
Market Cap				294.46M
Enterprise Value
Monthly Web Traffic				9.82K
Web Traffic Growth				0.04
Valuation
Raised Capital				75M

Metric
Revenue				153.73M
Revenue (LTM)
Revenue (NTM)
Gross Profit				146.91M
EBITDA				-82.46M
Operating Income				-89.28M
Net Income				-106.79M
EPS				-1.78
Diluted EPS				-1.78
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin				0.96
Operating Profit Margin				-0.58
EBITDA Margin				-0.54
Net Profit Margin				-0.69
Return on Equity				-0.71
Return on Assets				-0.23
Return on Capital Employed				-0.24

ILLU

COM:ILLUMINAS

Illuminas

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio				-1.56
P/B Ratio				2.42
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio				4.33
EV Multiple				-1.22

Metric
Days Sales Outstanding				124.77
Days Payables Outstanding
Days Inventory Outstanding				0.00
Operating Cycle				124.77
Cash Conversion Cycle				-111.15
Asset Turnover				0.38

Metric
Operating Cash Flow				-111.62M
Free Cash Flow				-115.93M
Cash Flow to Debt				-0.44
Operating Cash Flow/Sales				-0.44
Free Cash Flow Yield				-0.57

Metric
Cash & Equivalents				69.27M
Accounts Receivable				-28.96M
Inventory
Goodwill
Debt to Capitalization				0.62
Debt to Assets				0.09
Current Ratio				5.18
Quick Ratio				5.05

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue				0.50
R&D to Revenue				3.49
SG&A to Revenue				1.24